2. Signaling Pathways
  3. Epigenetics
  4. Small Interfering RNA (siRNA)

Small Interfering RNA (siRNA)

Small Interfering RNA (siRNA) is a small exogenous double-stranded RNA (dsRNA) (20-25 nucleotides), which triggers the RNA interference (RNAi) pathway. The short dsRNA unwinds and the sense strand is degraded. Antisense strand forms RNA induced silencing complex (RISC) with various protein components. The antisense strand retained in RISC is specifically complementary to the target gene mRNA. Meanwhile, RISC has nuclease activity, which can cut and degrade the target gene mRNA, and inhibit the expression of target gene. Incomplete complementarity results in mRNA translation inhibition.

Small Interfering RNA (siRNA) Related Products (29569):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-150150
    SiRNA Negative Control
    		99.24%
    SiRNA Negative Control is a siRNA of 21 nucleotides, and can be used as a negative control. SiRNA Negative Control has no homology to most known gene sequence. SiRNA Negative Control can be used in human, mouse and rat cells in vitro. SiRNA Negative Control can be used as experimental control benchmark, verification of experimental reliability and standardization reference. SiRNA Negative Control is a common negative control used in most research articles.
    SiRNA Negative Control
  • HY-132591A
    Inclisiran sodium
    		99.08%
    Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran sodium inhibits the transcription of PCSK9. Inclisiran sodium inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran sodium has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran sodium can be used in researches of hyperlipidemia and cardiovascular disease (CVD).
    Inclisiran sodium
  • HY-132609
    Patisiran sodium
    		99.09%
    Patisiran sodium is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran sodium specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran sodium can be used for the research of hereditary TTR amyloidosis.
    Patisiran sodium
  • HY-132591
    Inclisiran
    		99.48%
    Inclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of PCSK9. Inclisiran inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD).
    Inclisiran
  • HY-132610A
    Givosiran sodium
    		98.71%
    Givosiran (ALN-AS1) sodium is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran sodium downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels. Givosiran sodium demonstrates potent inhibitory activity against ALAS1 in mouse, rat, and cynomolgus monkey models. Givosiran sodium can be used for the research of acute hepatic porphyria (AHP).
    Givosiran sodium
  • HY-147262
    Etedesiran
    Etedesiran is a component of the AOC drug Delpacibart etedesiran (HY-177565), formed by the reaction of an siRNA that induces cleavage of mRNA encoding myotonic dystrophy protein kinase (MTPK or DMPK) with SMCC linker (HY-42360). Etedesiran carries a maleimide group at its terminus, which can react with cysteine or lysine and is used for the synthesis of AOC drugs. Etedesiran is applicable to research related to myotonic dystrophy type 1.
    Etedesiran
  • HY-147266C
    Elebsiran scramble negative control
    		98.03%
    Elebsiran scramble negative control is the scrambled sequence of Elebsiran (HY-147266), and its modification method is the same. Elebsiran scramble negative control can be used as the negative control for Elebsiran.
    Elebsiran scramble negative control
  • HY-P10942A
    CGN peptide TFA
    		98.10%
    CGN peptide TFA is a 13 amino acid peptide composed of D-amino acids, referred to as CGN peptide. CGN peptide TFA is the retro-inverso isomer of the l-peptide TGN (TGNYKALHPHNG) and can deliver siRNA to the blood-brain barrier (BBB). CGN peptide TFA can be used in Alzheimer's disease (AD) research.
    CGN peptide TFA
  • HY-168374
    DSPE-PEG2000-Mannose
    DSPE-PEG 2000-Mannose is a mannose-containing lipid. DSPE-PEG 2000-Mannose is used to prepare mannose-conjugated Liposome (Man-lipo) for siRNA delivery. Mannose-modified liposomes encapsulating IDO siRNA (Man-lipo-siIDO) preferentially knock down IDO expression in the draining lymph nodes and spleens of melanoma-bearing mice. Man-lipo-siIDO delays the onset time of melanoma and reduces tumor volume.
    DSPE-PEG2000-Mannose
  • HY-132610
    Givosiran
    Givosiran (ALN-AS1) is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels. Givosiran demonstrates potent inhibitory activity against ALAS1 in mouse, rat, and cynomolgus monkey models. Givosiran can be used for the research of acute hepatic porphyria (AHP).
    Givosiran
  • HY-132613
    Lumasiran sodium
    		99.21%
    Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
    Lumasiran sodium
  • HY-132588
    Lumasiran
    		98.77%
    Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1).
    Lumasiran
  • HY-156822
    FAM-labeled siRNA Negative Control
    		Pre-designed Set
    FAM-labeled siRNA Negative Control is a fluorescently labeled negative control in the siRNA set.
    FAM-labeled siRNA Negative Control
  • HY-132589
    Vutrisiran
    Vutrisiran (ALN-TTRsc02) is a liver-directed, investigational, small interfering ribonucleic acid (siRNA) agent. Vutrisiran can be used for transthyretin (TTR)-mediated amyloidosis research.
    Vutrisiran
  • HY-132606A
    Nedosiran sodium
    Nedosiran (DCR-PHXC) sodium is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran sodium represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran sodium is a GalNAc-dsRNA conjugate.
    Nedosiran sodium
  • HY-132589A
    Vutrisiran sodium
    Vutrisiran sodium (ALN-TTRsc02 sodium) is a liver-directed small interfering RNA (siRNA). Vutrisiran sodium targets the mRNA of transthyretin (TTR), and is applicable to studies on transthyretin (TTR)-mediated amyloidosis.
    Vutrisiran sodium
  • HY-132587
    Fitusiran
    Fitusiran (ALN-AT3SC) is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran enhances thrombin activity and increases Thrombin generation, thereby restoring hemostatic function. Fitusiran can be used in hemophilia-related research.
    Fitusiran
  • HY-143220
    SS(no Galnac)-Inclisiran sodium
    		98.05%
    SS (no Galnac)-Inclisiran sodium is the sense strand of Inclisiran (HY-132591) without GalNAc modification. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9. SS (no Galnac)-Inclisiran sodium can be used in cardiovascular disease research.
    SS(no Galnac)-Inclisiran sodium
  • HY-132596A
    Tivanisiran sodium
    Tivanisiran sodium (SYL1001 sodium) is a small interfering RNA (siRNA) targeting TRPV1 . Tivanisiran sodium induces the degradation of TRPV1 mRNA, thereby inhibiting protein synthesis. Tivanisiran sodium alleviates ocular discomfort and pain, and improves ocular hyperemia and tear quality. Tivanisiran sodium is applicable to research related to dry eye disease.
    Tivanisiran sodium
  • HY-147425A
    Zerlasiran sodium
    Zerlasiran (SLN360) sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.
    Zerlasiran sodium